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Background:  
Currently circulating influenza B viruses are resistant 
to adamantanes and, except for a low number of 
sporadic cases, most are sensitive to neuraminidase 
inhibitors (NI). Adamantanes are ineffective against 
influenza B viruses and although NI-resistant 
influenza B viruses have been rarely reported, 
recently in the United States was identified one cluster 
of influenza B viruses with reduced susceptibility to NI 
and with the I221V substitution in the active site of the 
neuraminidase (Garg et al.,2013). Despite the low 
prevalence of oseltamivir or zanamivir resistant 
influenza viruses, the constant evolution of influenza 
requires the monitoring of antiviral resistance among 
these viruses in the community. This is very important 
for the clinical management of severe influenza cases 
as to the detection of novel genetic markers 
associated with antiviral resistance.  
This study reports the antiviral susceptibility to 
neuraminidase inhibitors of influenza B viruses 
isolated in Portugal during the 2010/2011, 2011/2012 
and 2012/2013 seasons. 
Material and Methods:   
Over the period of 3 influenza seasons, 147 influenza 
B viral strains were analysed by phenotypic 
fluorescent assays (MUNANA) in order to assess their 
susceptibility to NI, oseltamivir and zanamivir. For this 
purpose, was determined the NI concentration 
required to inhibit 50% of each influenza virus 
neuraminidase activity (IC50). The IC50 baseline of 
influenza B viruses was calculated for both oseltamivir 
and zanamivir using the Robust Excel programme. 
The neuraminidase gene segments were also 
monitored for the presence of the main molecular 
markers, associated with the resistance to 
neuraminidase inhibitors in influenza B viruses, by 
sequencing the neuraminidase (NA) gene. 
Results:  
All analysed influenza B strains proved to be susceptible to oseltamivir and zanamivir.  
In the 2010/2011 season the determined IC50 values ranged from 5.58 to 71.88 nM for oseltamivir 
and from 0.83 to 10.94nM to zanamivir (Figures 1 and 2). The zanamivir IC50 median value was about 
8-fold lower than oseltamivir IC50 median value (Table I). Statistical analysis revealed the presence of 
one minor outlier (B/Lisboa/13/2010, 71.08nM) for oseltamivir (2-fold reduction in susceptibility) and 
four minor outliers (B/Lisboa/15/2010: 9.52 nM; B/Lisboa/19/2010: 9.25 nM; B/Lisboa/51/2010: 10.94 
nM and B/Lisboa/53/2010: 9.62 nM) for zanamivir (3-fold reduction in susceptibility) comparing to the 
median IC50 value (Figures 1 and 2).  
During the 2011/2012 season IC50 values ranged from 23.0 to 38.38 nM (oseltamivir) and from 2.97 
to 9.07nM (zanamivir).  In this season were not found minor or major outliers for both neuraminidase 
inhibitors (Figures 1 and 2).  
The IC50 values obtained in 2012/2013 ranged from 7.91 to 84.84 nM (oseltamivir) and from 1.48 to 
5.88 nM (zanamivir). During this last season 3 viral strains were classified as major outliers for 
oseltamivir: B/Castelo Branco_PT/176/2013 (IC50=49.61nM), B/Lisboa_PT/74/2013 (IC50=50.93nM) 
and B/Lisboa_PT/50/2013 with the highest IC50 value of 84.84nM) (Figure 1).  Were also found 6 
minor outliers for oseltamivir and 13 minor outliers for zanamivir (Figures 1 and 2).  
Along the three studied seasons, the median IC50 values for both NI were higher among the 
B/Victoria than B/Yamagata viruses (Table I).  
None of the actually known mutations associated with resistance of influenza B viruses to NI was 
found in the NA gene (R150K, D197E/N/Y, I221T/V, N294S, R374K and G407S) of the analysed 
viruses. 
Conclusions:  
Influenza B viruses isolated in Portugal during the last three seasons were susceptible to the neuraminidase inhibitors. Portuguese 
influenza B strains revealed higher susceptibility to zanamivir than to oseltamivir, as observed in other studies (Kawai et al., 2009). 
The oseltamivir IC50 values were also different between viruses from the B/Victoria and B/Yamagata lineages, however this was not 
statistically demonstrated due to the small number of analysed viruses. Among B/Yamagata strains the oseltamivir and zanamivir IC50 
values were higher in 2011/2012 than in 2010/2011 and 2012/2013 seasons. 
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Figure 1 –  Oseltamivir IC50 values for influenza B in 3 last flu seasons, 
between 2010 and 2013.  
Table I – Number of viruses analysed and oseltamivir and zanamivir IC50 baseline levels for influenza 
B in 3 last flu seasons, between 2010 and 2013 (total influenza B results and by lineage). 
Figure 2 –  Zanamivir IC50 values  for influenza B in 3 last flu seasons, 
between 2010 and 2013.  
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Oseltamivir Zanamivir 
n Oseltamivir n Zanamivir n Oseltamivir n Zanamivir n Oseltamivir n Zanamivir
B/Yamagata 2 10,55±2,57 2 1,73 ± 1,31 5 28,75±1,17 5 6,69 ± 1,57 80 14,85±1,38 80 2,82 ± 1,30
B/Victoria 49 31,25±1,55 46 3,79 ± 1,68 1 38,38 1 6,7 10 31,57±1,72 10 3,86 ± 1,52
B (Total) 51 30,73±1,61 48 3,75± 1,74 6 30,26±1,29 6 6,69 ± 1,42 90 15,14±1,41 90 2,85 ± 1,30
Influenza B 
lineage and 
total
2010/2011 2011/2012 2012/2013
Median ± Robust Standard Deviation Median ± Robust Standard Deviation Median ± Robust Standard Deviation 
